LIND, M., A. HAYES, M. CAPRNDA, D. PETROVIC, L. RODRIGO, Peter KRUŽLIAK and A. ZULLI. Inducible nitric oxide synthase: Good or bad? BIOMEDICINE & PHARMACOTHERAPY. PARIS: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2017, vol. 93, SEP 2017, p. 370-375. ISSN 0753-3322. Available from: https://dx.doi.org/10.1016/j.biopha.2017.06.036.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Inducible nitric oxide synthase: Good or bad?
Authors LIND, M. (36 Australia), A. HAYES (36 Australia), M. CAPRNDA (703 Slovakia), D. PETROVIC (705 Slovenia), L. RODRIGO (724 Spain), Peter KRUŽLIAK (703 Slovakia, guarantor, belonging to the institution) and A. ZULLI (36 Australia).
Edition BIOMEDICINE & PHARMACOTHERAPY, PARIS, ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2017, 0753-3322.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher France
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.457
RIV identification code RIV/00216224:14110/17:00099908
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.biopha.2017.06.036
UT WoS 000407923000040
Keywords in English Nitric oxide synthase (NOS); Inducible NOS (iNOS); Endothelial NOS (eNOS); Cyclooxygenase-2 (COX-2); COX-2; Oxidative stress; Cardiovascular diseases
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 7/2/2018 15:08.
Abstract
Nitric oxide synthases (NOS) are a family of isoforms responsible for the synthesis of the potent dilator nitric oxide (NO). Expression of inducible NOS (iNOS) occurs in conditions of inflammation, and produces large amounts of NO. In pathological conditions iNOS is regarded as a harmful enzyme and is proposed to be a major contributor to diseases of the cardiovascular system such as atherosclerosis. In this review, we address the notion that iNOS is a detrimental enzyme in disease and discuss its potentially beneficial roles. Additionally, we describe other molecules associated with iNOS in diseases such as atherosclerosis, and current research on therapeutic inhibitors tested to reduced pathology associated with cardiovascular diseases (CVD). (C) 2017 Elsevier Masson SAS. All rights reserved.
PrintDisplayed: 18/7/2024 14:18